W

hither Teva Pharmaceuticals (TEVA)?

After weeks of anticipation, the drug maker is starting a large-scale reorganization that involves 14,000 layoffs, or 25 percent of its workforce; closing or selling a “significant” number of 80 manufacturing plants; repricing or discontinuing some generics; closing or selling some R&D facilities and reviewing all R&D programs; and suspending dividends on ordinary shares and annual bonuses this year.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy